Drug Price Control: Lower Costs for Medicare Patients
This act aims to reduce drug costs for individuals covered by Medicare Part B. Drug manufacturers will be required to pay rebates if their drug prices increase faster than inflation. This could lead to lower out-of-pocket costs for patients, as their co-insurance will be based on an inflation-adjusted price.
Key points
Drug manufacturers must pay rebates if Medicare Part B drug prices increase faster than inflation.
Rebates apply to drugs with an annual cost per individual exceeding $100 (this amount will increase with inflation).
Patient co-insurance will be calculated based on the inflation-adjusted drug price, potentially lowering their expenses.
Rebate funds will be deposited into the Federal Supplementary Medical Insurance Trust Fund, potentially stabilizing Medicare.
Financial penalties are imposed on manufacturers who fail to pay required rebates.
Expired
Citizen Poll